Figure 2.
The Eclipse ICGM System was developed by Glysens, Inc. The implantable continuous glucose monitoring system (left) accurately measures the concentration of tissue fluid glucose, remains stable between infrequent recalibration periods, and reliably communicates with an external transmitter-receiver (right) using low-energy Bluetooth for more than one year (www.glysens.com).